{"abstract":"The National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to Braeburn Pharmaceuticals, Inc. (\"Braeburn\") located in Princeton, New Jersey to practice the inventions embodied in the patent applications listed in the SUPPLEMENTARY INFORMATION section of this notice.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2016/11/29/2016-28698.html","cfr_references":[],"citation":"81 FR 85982","comment_url":null,"comments_close_on":"2016-12-14","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NCI Technology Transfer Center on or before December 14, 2016 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2016-28698","effective_on":null,"end_page":85983,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2016/11/29/2016-28698.xml","html_url":"https://www.federalregister.gov/documents/2016/11/29/2016-28698/prospective-grant-of-exclusive-patent-license-development-and-commercialization-of-dopamine-d3","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2016-28698?publication_date=2016-11-29","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2016-11-29/2016-28698/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":123,"last_updated":"2026-08-25 02:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2016-11-29/pdf/2016-28698.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2016-28698.pdf?1480340781","publication_date":"2016-11-29","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2016/11/29/2016-28698.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T08:37:49Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":85982,"subtype":null,"title":"Prospective Grant of Exclusive Patent License: Development and Commercialization of Dopamine D3 Receptor Selective Antagonists/Partial Agonists for the Treatment of Opioid Use Disorder, Schizophrenia Bipolar Disorder and Tetrahydrocannabinol Dependence","toc_doc":"Development and Commercialization of Dopamine D3 Receptor Selective Antagonists/Partial Agonists for Treatment of Opioid Use Disorder, Schizophrenia Bipolar Disorder and Tetrahydrocannabinol Dependence","toc_subject":"Prospective Grants of Exclusive Patent Licenses:","topics":[],"type":"Notice","volume":81}